These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
265 related items for PubMed ID: 30385593
1. Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. Sobhy A, Fakhry M M, A Azeem H, Ashmawy AM, Omar Khalifa H. J Investig Med; 2019 Mar; 67(3):681-685. PubMed ID: 30385593 [Abstract] [Full Text] [Related]
5. Non-invasive models for predicting histology in patients with chronic hepatitis B. Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, Mak B, Oo AM, Lim SG. Liver Int; 2006 Aug; 26(6):666-72. PubMed ID: 16842322 [Abstract] [Full Text] [Related]
6. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777 [Abstract] [Full Text] [Related]
7. [Value of non-invasive models of liver fibrosis in judgment of treatment timing in chronic hepatitis B patients with ALT < 2×upper limit of normal]. Zhou QQ, Hu YB, Zhou K, Zhang WW, Li MH, Dong P, Di JG, Hong L, Du QW, Xie Y, Sun QF. Zhonghua Gan Zang Bing Za Zhi; 2016 Sep 20; 24(9):665-670. PubMed ID: 27788722 [Abstract] [Full Text] [Related]
9. Non-invasive assessment of liver fibrosis in chronic viral hepatitis. Orasan OH, Iancu M, Sava M, Saplontai-Pop A, Cozma A, Sarlea ST, Lungoci C, Ungureanu MI, Negrean V, Sampelean D, Dumitrascu DL. Eur J Clin Invest; 2015 Dec 20; 45(12):1243-51. PubMed ID: 26426402 [Abstract] [Full Text] [Related]
10. MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Appourchaux K, Dokmak S, Resche-Rigon M, Treton X, Lapalus M, Gattolliat CH, Porchet E, Martinot-Peignoux M, Boyer N, Vidaud M, Bedossa P, Marcellin P, Bièche I, Estrabaud E, Asselah T. Sci Rep; 2016 Oct 12; 6():34935. PubMed ID: 27731343 [Abstract] [Full Text] [Related]
14. Serum osteopontin predicts degree of hepatic fibrosis and serves as a biomarker in patients with hepatitis C virus infection. Matsue Y, Tsutsumi M, Hayashi N, Saito T, Tsuchishima M, Toshikuni N, Arisawa T, George J. PLoS One; 2015 Oct 12; 10(3):e0118744. PubMed ID: 25760884 [Abstract] [Full Text] [Related]
15. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, Schmidt MA, Lu M, Chronic Hepatitis Cohort Study (CHeCS) Investigators. J Viral Hepat; 2014 Dec 12; 21(12):930-7. PubMed ID: 24472062 [Abstract] [Full Text] [Related]
18. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations. Tseng PL, Wang JH, Hung CH, Tung HD, Chen TM, Huang WS, Liu SL, Hu TH, Lee CM, Lu SN. Kaohsiung J Med Sci; 2013 Jul 12; 29(7):385-95. PubMed ID: 23768703 [Abstract] [Full Text] [Related]